Welcome!

News Feed Item

Spina Bifida Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spina Bifida Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

Spina Bifida Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spina Bifida Global Clinical Trials Review, H2, 2014" provides data on the Spina Bifida clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spina Bifida. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spina Bifida. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Spina Bifida 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Spina Bifida to Central Nervous System Clinical Trials 16
Clinical Trials by Phase 17
In Progress Trials by Phase 18
Clinical Trials by Trial Status 19
Clinical Trials by End Point Status 20
Unaccomplished Trials of Spina Bifida 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Prominent Drugs 25
Clinical Trial Profiles 26
Clinical Trial Overview of Top Companies 26
Tengion, Inc. 26
Clinical Trial Overview of Tengion, Inc. 26
Clinical Trial Overview of Top Institutes / Government 27
Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 27
Centers for Disease Control and Prevention 28
Clinical Trial Overview of Centers for Disease Control and Prevention 28
William Beaumont Hospitals 29
Clinical Trial Overview of William Beaumont Hospitals 29
Aarhus University 30
Clinical Trial Overview of Aarhus University 30
Rennes University Hospital 31
Clinical Trial Overview of Rennes University Hospital 31
Baylor College of Medicine 32
Clinical Trial Overview of Baylor College of Medicine 32
UMC Utrecht Holding BV 33
Clinical Trial Overview of UMC Utrecht Holding BV 33
Universitaire Ziekenhuizen Leuven 34
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 34
University of New Mexico 35
Clinical Trial Overview of University of New Mexico 35
Duke University 36
Clinical Trial Overview of Duke University 36
Five Key Clinical Profiles 37
Appendix 56
Abbreviations 56
Definitions 56
Research Methodology 57
Secondary Research 57
About GlobalData 58
Contact Us 58
Disclaimer 58
Source 58

List of Tables

Spina Bifida Therapeutics, Global, Clinical Trials by Region, 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Spina Bifida Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Spina Bifida Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 12
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase, 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics, Global, Withdrawn Clinical Trials, 2014* 21
Spina Bifida Therapeutics, Global, Terminated Clinical Trials, 2014* 21
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 23
Spina Bifida Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 24
Spina Bifida Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 25
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Tengion, Inc., 2014* 26
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 27
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 28
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2014* 29
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Aarhus University, 2014* 30
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Rennes University Hospital, 2014* 31
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2014* 32
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by UMC Utrecht Holding BV, 2014* 33
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 34
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by University of New Mexico, 2014* 35
Spina Bifida Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 36

List of Figures

Spina Bifida Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Spina Bifida Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Spina Bifida Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Spina Bifida to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 13
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 14
Spina Bifida Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 15
Proportion of Spina Bifida to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 16
Spina Bifida Therapeutics, Global, Clinical Trials by Phase (%), 2014* 17
Spina Bifida Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 18
Spina Bifida Therapeutics, Global, Clinical Trials by Trial Status, 2014* 19
Spina Bifida Therapeutics Clinical Trials, Global, by End Point Status, 2014* 20
Spina Bifida Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 22
Spina Bifida Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 23
GlobalData Methodology 57

To order this report: Spina Bifida Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280944/Spina-Bifida-Global-Clinical-Trials-Review-H2-2014.html

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Cybersecurity is a critical component of software development in many industries including medical devices. However, code is not always written to be robust or secure from the unknown or the unexpected. This gap can make medical devices susceptible to cybersecurity attacks ranging from compromised personal health information to life-sustaining treatment. In his session at @ThingsExpo, Clark Fortney, Software Engineer at Battelle, will discuss how programming oversight using key methods can incre...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyor belt between the Software Factory and production stages. Artifacts are ...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.